BDNF and Alzheimer disease: The call for "multi-modal strategies" in AD treatment is growing—for example, combining anti-Aβ monoclonal antibodies with chronic inflammation modulators or pairing novel synaptoplastic molecules (e.g., BDNF analogs) with neuroprotective agents (Laczo et al., 2020; Yang et al., 2024).